<DOC>
	<DOCNO>NCT01557517</DOCNO>
	<brief_summary>Background : - Oral graft-versus-host disease ( GVHD ) possible complication bone marrow transplant . It result donor cell try attack recipient body . Symptoms include dry mouth , sensitivity pain taste certain spice flavor , painful swallowing . Steroids possible effective treatment GHVD , cause side effect give pill injection . Steroids give cream rinse form , apply directly site symptom , few side effect . However , effectiveness rinse test mouth . Researchers want see steroid call clobetasol use mouth rinse treat oral GHVD . Objectives : - To see clobetasol rinse safe effective treatment oral graft-versus-host disease . Eligibility : - Individuals least 12 year age oral GHVD allergic clobetasol . Design : - Participants screen physical exam medical history . Blood urine sample collect . They also oral exam , mouth tissue biopsy , test start study drug . - Participants separate two group . One group receive clobetasol ; placebo liquid . - Participants rinse mouth study liquid three time day meal 2 week . - After 2 week , participant another study visit blood test exams . - After study visit , participant start use clobetasol rinse . Those originally clobetasol use rinse another 2 week . Those originally placebo use rinse 4 week . - Participants follow-up exam end treatment ... .</brief_summary>
	<brief_title>Clobetasol Oral Graft-Versus-Host Disease</brief_title>
	<detailed_description>BACKGROUND : - Chronic Graft versus Host Disease ( cGVHD ) major late complication allogeneic hematopoietic stem cell transplantation . - The oral cavity second commonly affect area cGVHD major cause morbidity . - Clobetasol high-potency topical corticosteroid widely use variety inflammatory disorder skin oral mucosa . - Treatment oral cGVHD topical agent attractive strategy potentially avoid adverse effect associate systemic immunosuppression . OBJECTIVES : - To investigate efficacy topical clobetasol 0.05 % oral rinse oral chronic graftversus-host disease ( cGVHD ) ELIGIBILITY : - Patients age 12-99 year clinically significant oral cGVHD . DESIGN : - This randomize , double blind , placebo-controlled , pilot study clobetasol 0.05 % topical oral rinse open label extension period . - Patients rinse oral cavity 10cc clobetasol 0.05 % placebo oral rinse 2 minute 3 time day . - Treatment duration 2 week randomize phase 2-4 week open label phase . - Up 40 patient enrol pilot trial 34 evaluable patient assess .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>INCLUSION CRITERIA : Age : 12 year 99 year . Diagnosis : clinically significant oral cGVHD allogeneic HSCT severity score least 2 erythema subset and/or least 1 ulceration subset composite score great equal 20 Oral Mucositis Rating Scale ( OMRS ) scale confirm principal investigator ( PI ) , clinical study chair ( CSC ) , lead associate investigator ( LAI ) . Hematologic Function : Patients must platelet count great equal 20,000/microL time initial evaluation . Informed Consent : All patient legal representative ( patient &lt; 18 year old ) must sign IRB approve informed consent document ( cGVHD natural history protocol 04C0281 NCI protocol allow screen procedure ) prior perform study determine patient eligibility . After confirmation patient eligibility patient legal representative must sign protocol specific inform consent . For pediatric patient age appropriate assent obtain accordance NIH guideline . Patients must able rinse expectorate study medication rather swallow . Female patient must willing practice birth control ( include abstinence ) two month treatment , childbearing potential . Patients must ability willingness come Clinical Center biweekly followup appointment . No change systemic immunosuppressive therapy ( type intensity level ) within 2 week prior enrollment . A 7day washout period require patient currently use another oral topical treatment mouth lesion . Patients currently use clobetasol oral topical treatment eligible study . EXCLUSION CRITERIA : Documented hypersensitivity clobetasol . Use clobetasol ointment intraorally time last 6month period . Pregnant breastfeeding female due possible toxicity fetus infant . Inability understand investigational nature study provide inform consent . Patients , medical reason , unable comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 28, 2017</verification_date>
	<keyword>cGVHD</keyword>
	<keyword>Oral cGVHD</keyword>
	<keyword>Topical</keyword>
	<keyword>Oral Rinse</keyword>
	<keyword>Clobetasol</keyword>
	<keyword>Oral Graft-Versus-Host Disease</keyword>
	<keyword>GVHD</keyword>
</DOC>